Adriamycin 
Active substance: Doxorubicin
Manufacturer: Teva Pharmaceuticals
Extract from the prescribing information:
"Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy."
"Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) has been reported in patients treated with anthracyclines, including doxorubicin."
The above has been extracted from the Adriamycin prescribing information on the Teva webpages.